Thomas Lundbck

List of Publications by Year in Descending Order

63 papers	2,620 citations	28 h-index	50 g-index
77 ext. papers	3,153 ext. citations	7.4 avg, IF	4.59 L-index

#	Paper	IF	Citations
63	Design and development of photoswitchable DFG-Out RET kinase inhibitors.. *European Journal of Medicinal Chemistry*, **2022**, 234, 114226	6.8	1
62	Inhibition of the ubiquitin-proteasome system by an NQO1-activatable compound. *Cell Death and Disease*, **2021**, 12, 914	9.8	
61	A FabG inhibitor targeting an allosteric binding site inhibits several orthologs from Gram-negative ESKAPE pathogens. *Bioorganic and Medicinal Chemistry*, **2021**, 30, 115898	3.4	7
60	Design and development of a photoswitchable DFG-out kinase inhibitor. *Chemical Communications*, **2021**, 57, 10043-10046	5.8	4
59	: Implementation of Acoustic Dispensing and 384-Well Based Workflows to Improve Assay Capacity and Reduce Compound and Solvent Use in Early Drug Metabolism and Pharmacokinetics Profiling. *Assay and Drug Development Technologies*, **2021**, 19, 410-411	2.1	
58	Druggability Assessment of the NUDIX Hydrolase Protein Family as a Workflow for Target Prioritization. *Frontiers in Chemistry*, **2020**, 8, 443	5	4
57	A Fully Integrated Assay Panel for Early Drug Metabolism and Pharmacokinetics Profiling. *Assay and Drug Development Technologies*, **2020**, 18, 157-179	2.1	13
56	Synthesis, Evaluation and Proposed Binding Pose of Substituted Spiro-Oxindole Dihydroquinazolinones as IRAP Inhibitors. *ChemistryOpen*, **2020**, 9, 325-337	2.3	4
55	Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy. *EMBO Molecular Medicine*, **2020**, 12, e10419	12	14
54	Perspective on CETSA Literature: Toward More Quantitative Data Interpretation. *SLAS Discovery*, **2020**, 25, 118-126	3.4	16
53	Development of a chemical probe against NUDT15. *Nature Chemical Biology*, **2020**, 16, 1120-1128	11.7	5
52	Diamond Blackfan anemia is mediated by hyperactive Nemo-like kinase. *Nature Communications*, **2020**, 11, 3344	17.4	4
51	A Phenotypic Screening Assay Identifies Modulators of Diamond Blackfan Anemia. *SLAS Discovery*, **2019**, 24, 304-313	3.4	7
50	CETSA beyond Soluble Targets: a Broad Application to Multipass Transmembrane Proteins. *ACS Chemical Biology*, **2019**, 14, 1913-1920	4.9	31
49	Identification of inhibitors of Tartrate-resistant acid phosphatase (TRAP/ACP5) activity by small-molecule screening. *Chemical Biology and Drug Design*, **2018**, 92, 1255-1271	2.9	6
48	In Situ Target Engagement Studies in Adherent Cells. *ACS Chemical Biology*, **2018**, 13, 942-950	4.9	17
47	Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells. *Nature Communications*, **2018**, 9, 250	17.4	28

46	Small Molecule Screens Identify CDK8-Inhibitors As Candidate Diamond-Blackfan Anemia Drugs. *Blood*, **2018**, 132, 753-753	2.2	1
45	Quantitative Interpretation of Intracellular Drug Binding and Kinetics Using the Cellular Thermal Shift Assay. *Biochemistry*, **2018**, 57, 6715-6725	3.2	10
44	A drug screening assay on cancer cells chronically adapted to acidosis. *Cancer Cell International*, **2018**, 18, 147	6.4	10
43	Chemical Instability and Promiscuity of Arylmethylidenepyrazolinone-Based MDMX Inhibitors. *ACS Chemical Biology*, **2018**, 13, 2849-2854	4.9	8
42	Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies. *Nature Medicine*, **2017**, 23, 256-263	50.5	69
41	Identification of Triazolothiadiazoles as Potent Inhibitors of the dCTP Pyrophosphatase 1. *Journal of Medicinal Chemistry*, **2017**, 60, 2148-2154	8.3	12
40	Piperazin-1-ylpyridazine Derivatives Are a Novel Class of Human dCTP Pyrophosphatase 1 Inhibitors. *Journal of Medicinal Chemistry*, **2017**, 60, 4279-4292	8.3	14
39	Diverse heterocyclic scaffolds as dCTP pyrophosphatase 1 inhibitors. Part 2: Pyridone- and pyrimidinone-derived systems. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 3219-3225	2.9	3
38	Prediction of intracellular exposure bridges the gap between target- and cell-based drug discovery. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E6231-E6239	11.5	60
37	dUTPase inhibition augments replication defects of 5-Fluorouracil. *Oncotarget*, **2017**, 8, 23713-23726	3.3	18
36	Early Perspective. *Journal of Biomolecular Screening*, **2016**, 21, 1019-1033		19
35	Discovery of the First Potent and Selective Inhibitors of Human dCTP Pyrophosphatase 1. *Journal of Medicinal Chemistry*, **2016**, 59, 1140-1148	8.3	30
34	Identification of Drug-Like Inhibitors of Insulin-Regulated Aminopeptidase Through Small-Molecule Screening. *Assay and Drug Development Technologies*, **2016**, 14, 180-93	2.1	10
33	Inhibitors of the Cysteine Synthase CysM with Antibacterial Potency against Dormant Mycobacterium tuberculosis. *Journal of Medicinal Chemistry*, **2016**, 59, 6848-59	8.3	33
32	CETSA screening identifies known and novel thymidylate synthase inhibitors and slow intracellular activation of 5-fluorouracil. *Nature Communications*, **2016**, 7, 11040	17.4	96
31	Binding to and Inhibition of Insulin-Regulated Aminopeptidase by Macrocyclic Disulfides Enhances Spine Density. *Molecular Pharmacology*, **2016**, 89, 413-24	4.3	28
30	Aryl Sulfonamide Inhibitors of Insulin-Regulated Aminopeptidase Enhance Spine Density in Primary Hippocampal Neuron Cultures. *ACS Chemical Neuroscience*, **2016**, 7, 1383-1392	5.7	19
29	Virtual Screening for Transition State Analogue Inhibitors of IRAP Based on Quantum Mechanically Derived Reaction Coordinates. *Journal of Chemical Information and Modeling*, **2015**, 55, 1984-93	6.1	8

28	Structural Basis for the Specificity of Human NUDT16 and Its Regulation by Inosine Monophosphate. *PLoS ONE*, **2015**, 10, e0131507	3.7	15
27	Immunomodulatory activity of commonly used drugs on Fc-receptor-mediated human natural killer cell activation. *Cancer Immunology, Immunotherapy*, **2014**, 63, 627-41	7.4	19
26	The cellular thermal shift assay for evaluating drug target interactions in cells. *Nature Protocols*, **2014**, 9, 2100-22	18.8	559
25	Microwave Heated Flow Synthesis of Spiro-oxindole Dihydroquinazolinone Based IRAP Inhibitors. *Organic Process Research and Development*, **2014**, 18, 1582-1588	3.9	34
24	Inhibition of Insulin-Regulated Aminopeptidase (IRAP) by Arylsulfonamides. *ChemistryOpen*, **2014**, 3, 256-63	2.3	15
23	Controversies in ASSAY and drug development technologies: a focus on assessing irreproducibility. *Assay and Drug Development Technologies*, **2014**, 12, 443-51	2.1	1
22	MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. *Nature*, **2014**, 508, 215-21	50.4	326
21	Structure-activity relationships of synthetic cordycepin analogues as experimental therapeutics for African trypanosomiasis. *Journal of Medicinal Chemistry*, **2013**, 56, 9861-73	8.3	36
20	In vitro and in vivo activities of 2-aminopyrazines and 2-aminopyridines in experimental models of human African trypanosomiasis. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 1012-8	5.9	9
19	A Robust Screening Assay For Diamond Blackfan Anemia Candidate Drugs. *Blood*, **2013**, 122, 2472-2472	2.2	
18	A novel assay of cellular stearoyl-CoA desaturase activity of primary rat hepatocytes by HPLC. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2010**, 878, 2427-32	2.2	6
17	N-Benzyl-indolo carboxylic acids: Design and synthesis of potent and selective adipocyte fatty-acid binding protein (A-FABP) inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 1745-8	2.9	81
16	Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 4445-8	2.9	63
15	Substituted benzylamino-6-(trifluoromethyl)pyrimidin-4(1H)-ones: a novel class of selective human A-FABP inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 4449-52	2.9	55
14	On the Nature of Solvent Effects on Redox Properties. *Journal of Physical Chemistry A*, **2004**, 108, 4805-4811	2.8	30
13	Structure-based screening as applied to human FABP4: a highly efficient alternative to HTS for hit generation. *Journal of the American Chemical Society*, **2002**, 124, 11874-80	16.4	45
12	Oligomerization of the chromatin-structuring protein H-NS. *Molecular Microbiology*, **2000**, 36, 962-72	4.1	107
11	Characterization of sequence-specific DNA binding by the transcription factor Oct-1. *Biochemistry*, **2000**, 39, 7570-9	3.2	34

10	Sequence-specific DNA binding by the glucocorticoid receptor DNA-binding domain is linked to a salt-dependent histidine protonation. *Biochemistry*, **2000**, 39, 8909-16	3.2	14
9	Oct-1 POU and octamer DNA co-operate to recognise the Bob-1 transcription co-activator via induced folding. *Journal of Molecular Biology*, **1999**, 288, 941-52	6.5	47
8	Thermodynamic characterization of non-sequence-specific DNA-binding by the Sso7d protein from Sulfolobus solfataricus. *Journal of Molecular Biology*, **1998**, 276, 775-86	6.5	79
7	Structure and dynamics of the glucocorticoid receptor DNA-binding domain: comparison of wild type and a mutant with altered specificity. *Biochemistry*, **1997**, 36, 11188-97	3.2	18
6	Salt Dependence of the Free Energy, Enthalpy, and Entropy of Nonsequence Specific DNA Binding. *The Journal of Physical Chemistry*, **1996**, 100, 17690-17695		35
5	Sequence-specific DNA-binding dominated by dehydration. *Proceedings of the National Academy of Sciences of the United States of America*, **1996**, 93, 4754-9	11.5	65
4	Thermodynamics of sequence-specific protein-DNA interactions. *Biophysical Chemistry*, **1996**, 62, 121-39	3.5	53
3	Solution structure and DNA-binding properties of a thermostable protein from the archaeon Sulfolobus solfataricus. *Nature Structural Biology*, **1994**, 1, 808-19		143
2	Thermodynamics of sequence-specific glucocorticoid receptor-DNA interactions. *Biochemistry*, **1994**, 33, 5955-65	3.2	35
1	Thermodynamics of the glucocorticoid receptor-DNA interaction: binding of wild-type GR DBD to different response elements. *Biochemistry*, **1993**, 32, 5074-82	3.2	50